GleamWall
中文EN

XNCR Xencor Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%

Returns

ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x

Cash quality & payout

Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$116.52M$51.22M$4.52M$28.24M$21.00M$43.61M$32.73M$70.02M
R&D expense$84.30M$71.91M$64.67M$64.82M$54.37M$61.66M$58.58M$51.06M
SG&A expense$9.36M$16.38M$17.71M$17.04M$14.15M$15.12M$17.34M$14.91M
Operating income$22.86M-$37.07M-$77.86M-$53.63M-$47.52M-$33.17M-$43.18M$4.05M
Interest expense$4.11M$7.35M$4.70M$7.35M$7.67M$8.24M$8.66M$33.93M
Pretax income$39.26M-$21.92M-$128.64M-$4.27M-$6.03M-$31.07M-$48.27M-$52.63M
Income tax-$175,000-$190,000$280,000$2.39M$0-$250,000$367,000$1.50M
Net income$39.44M-$21.73M-$128.92M-$6.65M-$6.03M-$30.82M-$48.42M-$53.48M
EBITDA$24.96M-$34.77M-$75.30M-$51.05M-$45.12M-$30.77M-$40.49M$7.04M
EPS (basic)0.52-0.29-1.71—-0.08-0.41-0.66—
EPS (diluted)0.50-0.29-1.71—-0.08-0.41-0.66—
Weighted avg. shares (diluted)78.35M75.86M75.25M—74.41M74.28M73.67M—
Balance sheet
Cash & equivalents$59.62M$44.66M$14.17M$54.07M$28.29M$44.73M$39.96M$41.26M
Receivables$64.84M$42.23M$12.00M$29.30M$21.80M$47.55M$37.78M$60.85M
Current assets$498.66M$523.21M$482.86M$599.82M$518.44M$513.15M$521.27M$577.60M
PP&E, net$49.78M$50.01M$51.49M$53.31M$54.59M$56.79M$58.81M$59.80M
Intangibles$5.05M$6.52M$7.60M$8.38M$9.47M$11.25M$13.36M$18.48M
Total assets$770.50M$724.96M$736.85M$875.50M$868.81M$879.42M$904.69M$951.95M
Current liabilities$76.27M$81.86M$73.46M$95.91M$86.48M$96.08M$88.44M$87.43M
Short-term debt$23.13M$27.36M$26.41M$43.27M$45.36M$50.29M$52.54M$48.45M
Long-term debt$71.93M$77.54M$82.12M$76.48M$87.78M$94.74M$101.84M$115.16M
Total debt$95.06M$104.89M$108.53M$119.75M$133.14M$145.02M$154.38M$163.61M
Total liabilities$210.07M$221.73M$221.21M$239.91M$243.50M$259.07M$264.81M$277.92M
Shareholders' equity$560.43M$503.23M$515.63M$635.59M$625.32M$620.35M$639.87M$677.61M
Net debt$35.44M$60.23M$94.36M$65.68M$104.85M$100.29M$114.42M$122.34M
Shares outstanding74.76M74.33M74.06M71.87M71.34M71.30M71.14M70.26M
Cash flow statement
Operating cash flow$2.64M-$55.66M-$67.63M-$51.71M-$30.82M-$36.37M-$16.22M-$55.58M
Capital expenditure$1.80M$538,000$610,000$1.14M$183,000$383,000$1.44M$1.66M
Free cash flow$838,000-$56.20M-$68.24M-$52.85M-$31.00M-$36.75M-$17.66M-$57.24M
Investing cash flow$7.33M$85.12M$26.68M$71.17M$14.67M$40.48M$13.67M$57.25M
Financing cash flow$9.99M$1.03M$950,000$6.32M$0$662,000$1.25M$10.17M
Depreciation & amortization$2.10M$2.30M$2.57M$2.58M$2.40M$2.40M$2.69M$2.99M
Stock-based compensation$9.43M$9.19M$9.56M$10.19M$10.09M$10.74M$12.21M$12.33M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.